News

Johnson & Johnson Trials Reveal Promising Psoriasis Treatment

Johnson & Johnson Trials Reveal Promising Psoriasis Treatment

Exciting Developments in Psoriasis Treatments

Johnson & Johnson (NYSE: JNJ) and Protagonist Therapeutics Inc. (NASDAQ: PTGX) recently announced encouraging results from their Phase 3 ICONIC-ADVANCE 1 and 2 trials involving icotrokinra. This treatment was tested against deucravacitinib in individuals suffering from moderate to severe plaque psoriasis.

Key Outcomes from the ICONIC-ADVANCE Trials

The studies revealed that icotrokinra successfully met both primary endpoints when compared to a placebo at Week 16. The adverse event rates were comparable. Notably, icotrokinra demonstrated a significant superiority over Bristol-Myers Squibb Co.’s (NYSE: BMY) Sotyktu (deucravacitinib) at various time points in adult subjects.

Superior Skin Clearance

In terms of effectiveness, icotrokinra offered enhanced skin clearance compared to placebo by Week 16 and outperformed deucravacitinib during Weeks 16 and 24. These findings highlight icotrokinra's potential as a more effective treatment option for patients.

Adverse Events Comparison

Moreover, icotrokinra displayed similar adverse event rates to the placebo group, with no new safety signals reported. Interestingly, the rates of adverse events were numerically lower when compared to deucravacitinib through Week 24.

Future Studies on Icotrokinra

In addition to the ICONIC-ADVANCE trials, Johnson & Johnson has commenced the Phase 3 ICONIC-ASCEND study. This ambitious study aims to assess the efficacy of icotrokinra, an oral medication, against Stelara (ustekinumab), an injectable biologic treatment for psoriasis.

Long-Term Efficacy and Safety

The data shared so far suggest that icotrokinra maintains positive skin clarity and a favorable safety profile up to Week 52. Notably, no new safety concerns have emerged from the ICONIC-LEAD withdrawal/re-treatment study.

Remarkable PASI 90 Response Rates

By Week 52, among adults treated with icotrokinra who initially responded positively to treatment, 84% who were then re-treated with icotrokinra maintained their PASI 90 response, compared to just 21% of those who switched to a placebo.

Impact on Adolescents

Excitingly, among adolescents treated with icotrokinra over the full 52 weeks, 86% achieved a PASI 90 response. Similarly, 77% of those who transitioned from placebo to icotrokinra at Week 16 also reached this impressive treatment milestone.

Current Stock Movements

In light of these developments, JNJ stock witnessed a slight increase of 0.22%, trading at $176.85. Such positive news could potentially influence market perceptions and stock performance moving forward.

Frequently Asked Questions

What is icotrokinra?

Icotrokinra is an investigational oral medication aimed at treating moderate to severe psoriasis.

How does icotrokinra compare to existing treatments?

The recent trials indicate that icotrokinra shows superior effectiveness compared to standard treatments like deucravacitinib.

Are there any safety concerns with icotrokinra?

So far, the trials indicate similar safety profiles when compared to placebo, with no new safety signals reported.

What is the significance of the PASI 90 response rate?

The PASI 90 response rate signifies a 90% improvement in psoriasis symptoms, a crucial measure of treatment efficacy.

What is the outlook for Johnson & Johnson stock?

With positive trial results, JNJ stock's performance may be influenced positively as market confidence grows.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 22

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 64

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 24

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 78

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Updated Category News Views 131

Avicanna's 5th Medical Symposium on Cannabinoid Medicine On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and...

Continue Reading
Gordian's Exciting New Initiative for Public Facility Planning

Updated Category News Views 277

Gordian's New Sourcewell Contract Gordian, a well-known provider of data-driven solutions for various phases of the building lifecycle, has recently secured a significant contract with Sourcewell. This partnership will broaden Gordian’s offerings to numerous government and educational organizations eager to enhance their facility planning capabilities. Facilitating...

Continue Reading
Paramount Global CFO Transition: A New Era Begins

Updated Category News Views 251

Paramount Global Announces Significant Leadership Change Paramount Global (NASDAQ: PARA) has made a noteworthy announcement regarding its executive leadership. Naveen Chopra, who has been serving as the Chief Financial Officer and Executive Vice President, will be departing from the company to explore new opportunities. The company's Board of Directors has stated that...

Continue Reading
Explore the Potential of Axsome, CRISPR, and Pfizer Stocks

Updated Category News Views 134

Back in 2023, the stock market was a mixed bag, with plenty of sectors showing serious signs of overvaluation. You had legends like Warren Buffett sitting on a mountain of cash, clearly indicating he saw overpriced stocks everywhere. When seasoned investors hit the brakes on buying due to high valuations, it’s like an alarm bell for everyone else—caution was in the...

Continue Reading
Boeing's Production Delays and Its Impact on Suppliers

Updated Category News Views 245

A Closer Look at Boeing's Production Setbacks Boeing Co has recently notified its suppliers about a significant change to a key production milestone for its 737 MAX aircraft. This adjustment, which extends the timeline by six months, has raised concerns within the aviation industry. Sources indicate that the new objective is to achieve an output of 42 jets per month by...

Continue Reading